Relapse Prevention Study in Newly Abstinent Smokers

Withdrawn before enrolling · Phase 2 · Has a placebo group

Conditions studied: Substance Dependence

In brief

The purpose of this study is to determine the effect of GSK598809 as compared to placebo in preventing recently-quit smokers from going back to smoking.

Key facts

Study ID

NCT00793468

Run by

GlaxoSmithKline

People needed

0

Starts

2008-12-01

Expected to finish

2008-12-01

Last updated by the study team

2016-02-15

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• has smoked at least 10 cigarettes a day for at least 2 years
• has had multiple previous attempts to quit smoking and relapsed to smoking.
• generally healthy

You may not qualify if…

• cannot be using smokeless tobacco of any type or has tried to quit with medicine.
• does not abuse alcohol or drugs
• certain emotional problems being treated with medications
• pregnant or breast feeding female

Where it is running

• GSK Investigational Site — DeLand, Florida, United States
• GSK Investigational Site — Pembroke Pines, Florida, United States
• GSK Investigational Site — Stockbridge, Georgia, United States
• GSK Investigational Site — Overland Park, Kansas, United States
• GSK Investigational Site — Las Vegas, Nevada, United States
• GSK Investigational Site — Rochester, New York, United States
• GSK Investigational Site — Raleigh, North Carolina, United States
• GSK Investigational Site — Portland, Oregon, United States
• GSK Investigational Site — Philadelphia, Pennsylvania, United States
• GSK Investigational Site — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.